{"id":326361,"date":"2026-10-26T11:37:39","date_gmt":"2026-10-26T06:07:39","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=326361"},"modified":"2026-10-26T11:37:39","modified_gmt":"2026-10-26T06:07:39","slug":"fermentation-based-ingredients-maker-custom-synthesis-specialist-and-research-driven-pharma-company-stocks-roadmap-northstar-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/fermentation-based-ingredients-maker-custom-synthesis-specialist-and-research-driven-pharma-company-stocks-roadmap-northstar-list\/","title":{"rendered":"3 Fermentation-Based Ingredients Maker, Custom Synthesis Specialist and Research-Driven Pharma Company Stocks With a Strong Future Roadmap: Concord Biotech, Neuland Laboratories and Glenmark Pharmaceuticals"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Concord Biotech, Neuland Laboratories and Glenmark Pharmaceuticals: ROE of 12.9% to 28.1% and FY22 to FY26 revenue CAGR of 8.7% to 21.1%. Prices as of 23 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three biopharma, API and innovation pharma stocks to watch are Concord Biotech, Neuland Laboratories and Glenmark Pharmaceuticals. Their return on equity ranges from 12.9% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 21.1%. Glenmark Pharmaceuticals has the highest return on equity at 28.1%, while Neuland Laboratories has the fastest revenue growth at 21.1% a year. Prices are based on the 23 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Biopharma, API and innovation pharma stocks let investors follow companies that serve a growing part of the Indian economy. Concord Biotech, Neuland Laboratories and Glenmark Pharmaceuticals cover a fermentation-based ingredients maker, a custom synthesis specialist and a research-driven pharma company.<\/p>\n<p>This list covers three biopharma, API and innovation pharma stocks with complete current figures: Concord Biotech, Neuland Laboratories and Glenmark Pharmaceuticals. Every figure comes from the latest reported financials and the 23 October 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=fermentation-based-ingredients-maker-custom-synthesis-specialist-and-research-driven-pharma-company-stocks-roadmap-northstar-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/fermentation-based-ingredients-maker-custom-synthesis-specialist-and-research-driven-pharma-company-stocks-roadmap-northstar-list\/#What_Are_Biopharma_API_and_Innovation_Pharma_Stocks\" title=\"What Are Biopharma, API and Innovation Pharma Stocks?\">What Are Biopharma, API and Innovation Pharma Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/fermentation-based-ingredients-maker-custom-synthesis-specialist-and-research-driven-pharma-company-stocks-roadmap-northstar-list\/#Biopharma_API_and_Innovation_Pharma_Stocks_at_a_Glance\" title=\"Biopharma, API and Innovation Pharma Stocks at a Glance\">Biopharma, API and Innovation Pharma Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/fermentation-based-ingredients-maker-custom-synthesis-specialist-and-research-driven-pharma-company-stocks-roadmap-northstar-list\/#Why_Do_Biopharma_API_and_Innovation_Pharma_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Biopharma, API and Innovation Pharma Stocks Have a Strong Roadmap in India?\">Why Do Biopharma, API and Innovation Pharma Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/fermentation-based-ingredients-maker-custom-synthesis-specialist-and-research-driven-pharma-company-stocks-roadmap-northstar-list\/#Why_Concord_Biotech_Features_Among_These_Biopharma_API_and_Innovation_Pharma_Stocks\" title=\"Why Concord Biotech Features Among These Biopharma, API and Innovation Pharma Stocks\">Why Concord Biotech Features Among These Biopharma, API and Innovation Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/fermentation-based-ingredients-maker-custom-synthesis-specialist-and-research-driven-pharma-company-stocks-roadmap-northstar-list\/#Why_Neuland_Laboratories_Features_Among_These_Biopharma_API_and_Innovation_Pharma_Stocks\" title=\"Why Neuland Laboratories Features Among These Biopharma, API and Innovation Pharma Stocks\">Why Neuland Laboratories Features Among These Biopharma, API and Innovation Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/fermentation-based-ingredients-maker-custom-synthesis-specialist-and-research-driven-pharma-company-stocks-roadmap-northstar-list\/#Why_Glenmark_Pharmaceuticals_Features_Among_These_Biopharma_API_and_Innovation_Pharma_Stocks\" title=\"Why Glenmark Pharmaceuticals Features Among These Biopharma, API and Innovation Pharma Stocks\">Why Glenmark Pharmaceuticals Features Among These Biopharma, API and Innovation Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/fermentation-based-ingredients-maker-custom-synthesis-specialist-and-research-driven-pharma-company-stocks-roadmap-northstar-list\/#Concord_Biotech_vs_Neuland_Laboratories_vs_Glenmark_Pharmaceuticals_on_Key_Financials\" title=\"Concord Biotech vs Neuland Laboratories vs Glenmark Pharmaceuticals on Key Financials\">Concord Biotech vs Neuland Laboratories vs Glenmark Pharmaceuticals on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/fermentation-based-ingredients-maker-custom-synthesis-specialist-and-research-driven-pharma-company-stocks-roadmap-northstar-list\/#Key_Risks_to_Check_Before_Investing_in_Biopharma_API_and_Innovation_Pharma_Stocks\" title=\"Key Risks to Check Before Investing in Biopharma, API and Innovation Pharma Stocks\">Key Risks to Check Before Investing in Biopharma, API and Innovation Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/fermentation-based-ingredients-maker-custom-synthesis-specialist-and-research-driven-pharma-company-stocks-roadmap-northstar-list\/#Final_Thoughts_on_Biopharma_API_and_Innovation_Pharma_Stocks\" title=\"Final Thoughts on Biopharma, API and Innovation Pharma Stocks\">Final Thoughts on Biopharma, API and Innovation Pharma Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/fermentation-based-ingredients-maker-custom-synthesis-specialist-and-research-driven-pharma-company-stocks-roadmap-northstar-list\/#What_are_biopharma_API_and_innovation_pharma_stocks\" title=\"What are biopharma, API and innovation pharma stocks?\">What are biopharma, API and innovation pharma stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/fermentation-based-ingredients-maker-custom-synthesis-specialist-and-research-driven-pharma-company-stocks-roadmap-northstar-list\/#Which_biopharma_API_and_innovation_pharma_stocks_are_covered_in_this_list\" title=\"Which biopharma, API and innovation pharma stocks are covered in this list?\">Which biopharma, API and innovation pharma stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/fermentation-based-ingredients-maker-custom-synthesis-specialist-and-research-driven-pharma-company-stocks-roadmap-northstar-list\/#Why_do_biopharma_API_and_innovation_pharma_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do biopharma, API and innovation pharma stocks have a strong future roadmap in India?\">Why do biopharma, API and innovation pharma stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/fermentation-based-ingredients-maker-custom-synthesis-specialist-and-research-driven-pharma-company-stocks-roadmap-northstar-list\/#How_has_Concord_Biotech_performed_financially\" title=\"How has Concord Biotech performed financially?\">How has Concord Biotech performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/fermentation-based-ingredients-maker-custom-synthesis-specialist-and-research-driven-pharma-company-stocks-roadmap-northstar-list\/#How_has_Neuland_Laboratories_performed_financially\" title=\"How has Neuland Laboratories performed financially?\">How has Neuland Laboratories performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/fermentation-based-ingredients-maker-custom-synthesis-specialist-and-research-driven-pharma-company-stocks-roadmap-northstar-list\/#How_has_Glenmark_Pharmaceuticals_performed_financially\" title=\"How has Glenmark Pharmaceuticals performed financially?\">How has Glenmark Pharmaceuticals performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/fermentation-based-ingredients-maker-custom-synthesis-specialist-and-research-driven-pharma-company-stocks-roadmap-northstar-list\/#What_risks_should_investors_check_before_buying_biopharma_API_and_innovation_pharma_stocks\" title=\"What risks should investors check before buying biopharma, API and innovation pharma stocks?\">What risks should investors check before buying biopharma, API and innovation pharma stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/fermentation-based-ingredients-maker-custom-synthesis-specialist-and-research-driven-pharma-company-stocks-roadmap-northstar-list\/#Is_this_list_of_biopharma_API_and_innovation_pharma_stocks_investment_advice\" title=\"Is this list of biopharma, API and innovation pharma stocks investment advice?\">Is this list of biopharma, API and innovation pharma stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Biopharma_API_and_Innovation_Pharma_Stocks\"><\/span><strong>What Are Biopharma, API and Innovation Pharma Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Biopharma, API and innovation pharma stocks are listed drug makers that supply fermentation ingredients, complex active ingredients and branded and generic medicines. Their earnings depend on customer contracts, regulatory approvals and the progress of new products.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Biopharma_API_and_Innovation_Pharma_Stocks_at_a_Glance\"><\/span><strong>Biopharma, API and Innovation Pharma Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/concordbio\/concord-biotech-ltd-share-price-today\">Concord Biotech<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,229.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13,421<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">49.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.00<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/neulandlab\/neuland-laboratories-ltd-share-price-today\">Neuland Laboratories<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18,865<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">24,665<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">49.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.16<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/glenmark\/glenmark-pharmaceuticals-ltd-share-price-today\">Glenmark Pharmaceuticals<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,166.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">60,103<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">33.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">35.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">28.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.06<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Glenmark Pharmaceuticals trades at a P\/E below the industry P\/E, while Concord Biotech and Neuland Laboratories trade above it, which reflects the growth the market already expects. Readers comparing biopharma, API and innovation pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Biopharma_API_and_Innovation_Pharma_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Biopharma, API and Innovation Pharma Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Biopharma, API and innovation pharma stocks have a strong roadmap in India because global innovators outsource complex manufacturing, and Indian firms with strong science are moving into specialty and innovative medicines.<\/p>\n<ul>\n<li><strong>Complex chemistry.<\/strong> Few suppliers can make difficult molecules at scale.<\/li>\n<li><strong>Custom manufacturing.<\/strong> Innovator contracts bring multi-year demand.<\/li>\n<li><strong>Innovation pipeline.<\/strong> New drug programmes create fresh growth options.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Concord_Biotech_Features_Among_These_Biopharma_API_and_Innovation_Pharma_Stocks\"><\/span><strong>Why Concord Biotech Features Among These Biopharma, API and Innovation Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the biopharma, API and innovation pharma stocks on this list, Concord Biotech is a Gujarat-based biopharma company that makes fermentation-based active ingredients such as immunosuppressants, oncology drugs and anti-infectives for global pharma customers.<\/p>\n<p>In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%.<\/p>\n<p>Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P\/E of 49.2, above the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.<\/p>\n<p><strong>What to watch:<\/strong> Monitor the pace of new product introductions and the contribution from formulations.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Neuland_Laboratories_Features_Among_These_Biopharma_API_and_Innovation_Pharma_Stocks\"><\/span><strong>Why Neuland Laboratories Features Among These Biopharma, API and Innovation Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the fermentation ingredient company shares on this list, Neuland Laboratories, based in Hyderabad, makes active pharmaceutical ingredients for generic drugs and runs a custom manufacturing business that supplies innovator companies.<\/p>\n<p>The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P\/E of 49.5, above the industry P\/E of 36.0.<\/p>\n<p>Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%.<\/p>\n<p><strong>Roadmap:<\/strong> The company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.<\/p>\n<p><strong>What to watch:<\/strong> Custom manufacturing revenue can move between quarters, so review the full-year trend.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Glenmark_Pharmaceuticals_Features_Among_These_Biopharma_API_and_Innovation_Pharma_Stocks\"><\/span><strong>Why Glenmark Pharmaceuticals Features Among These Biopharma, API and Innovation Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Glenmark Pharmaceuticals is a research-driven pharma company with branded generics in India and other emerging markets, generics in the United States and Europe, and an innovation arm focused on new drugs.<\/p>\n<p>Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%.<\/p>\n<p>In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P\/E of 33.4, below the industry P\/E of 35.7.<\/p>\n<p><strong>Roadmap:<\/strong> The company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.<\/p>\n<p><strong>What to watch:<\/strong> Track new product launches, progress in the innovation pipeline and balance sheet strength.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Concord_Biotech_vs_Neuland_Laboratories_vs_Glenmark_Pharmaceuticals_on_Key_Financials\"><\/span><strong>Concord Biotech vs Neuland Laboratories vs Glenmark Pharmaceuticals on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three biopharma, API and innovation pharma stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Concord Biotech<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">736<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,107<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10.7%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">259<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.4%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Neuland Laboratories<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">953<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,053<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">21.1%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">364<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.7%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Glenmark Pharmaceuticals<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12,472<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17,443<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8.7%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,362<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7.8%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Glenmark Pharmaceuticals posts the highest return on equity in this group at 28.1%. Glenmark Pharmaceuticals has the largest FY26 revenue at Rs 17,443 crore, and Neuland Laboratories shows the fastest revenue growth with a 21.1% compound annual rate. A useful habit with biopharma, API and innovation pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Biopharma_API_and_Innovation_Pharma_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Biopharma, API and Innovation Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these biopharma, API and innovation pharma stocks, the main points are:<\/p>\n<ul>\n<li><strong>Regulatory checks.<\/strong> Plant inspections can affect approvals.<\/li>\n<li><strong>Contract timing.<\/strong> Large orders can shift between quarters.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter biopharma, API and innovation pharma stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Biopharma_API_and_Innovation_Pharma_Stocks\"><\/span><strong>Final Thoughts on Biopharma, API and Innovation Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Biopharma, API and innovation pharma stocks reward investors who follow demand trends, order books and margins together. Concord Biotech, Neuland Laboratories and Glenmark Pharmaceuticals each have a clear plan to grow. Based on the 23 October 2026 close, Concord Biotech trades at Rs 1,229.3, Neuland Laboratories at Rs 18,865 and Glenmark Pharmaceuticals at Rs 2,166.6.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track biopharma, API and innovation pharma stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_biopharma_API_and_innovation_pharma_stocks\"><\/span><strong>What are biopharma, API and innovation pharma stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Biopharma, API and innovation pharma stocks are listed drug makers that supply fermentation ingredients, complex active ingredients and branded and generic medicines. Their earnings depend on customer contracts, regulatory approvals and the progress of new products. This list looks at three of them, Concord Biotech, Neuland Laboratories and Glenmark Pharmaceuticals, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_biopharma_API_and_innovation_pharma_stocks_are_covered_in_this_list\"><\/span><strong>Which biopharma, API and innovation pharma stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Concord Biotech, Neuland Laboratories and Glenmark Pharmaceuticals. Based on the 23 October 2026 close, Concord Biotech traded at Rs 1,229.3, Neuland Laboratories at Rs 18,865 and Glenmark Pharmaceuticals at Rs 2,166.6. Their return on equity ranges from 12.9% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 21.1%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_biopharma_API_and_innovation_pharma_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do biopharma, API and innovation pharma stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Biopharma, API and innovation pharma stocks have a strong roadmap in India because global innovators outsource complex manufacturing, and Indian firms with strong science are moving into specialty and innovative medicines. The main drivers are as follows. Complex chemistry. Few suppliers can make difficult molecules at scale. Custom manufacturing. Innovator contracts bring multi-year demand. Innovation pipeline. New drug programmes create fresh growth options. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Concord_Biotech_performed_financially\"><\/span><strong>How has Concord Biotech performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P\/E of 49.2, above the industry P\/E of 36.0. Looking ahead, the company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Neuland_Laboratories_performed_financially\"><\/span><strong>How has Neuland Laboratories performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P\/E of 49.5, above the industry P\/E of 36.0. Looking ahead, the company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Glenmark_Pharmaceuticals_performed_financially\"><\/span><strong>How has Glenmark Pharmaceuticals performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P\/E of 33.4, below the industry P\/E of 35.7. Looking ahead, the company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_biopharma_API_and_innovation_pharma_stocks\"><\/span><strong>What risks should investors check before buying biopharma, API and innovation pharma stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying biopharma, API and innovation pharma stocks. Regulatory checks. Plant inspections can affect approvals. Contract timing. Large orders can shift between quarters. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_biopharma_API_and_innovation_pharma_stocks_investment_advice\"><\/span><strong>Is this list of biopharma, API and innovation pharma stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are biopharma, API and innovation pharma stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Biopharma, API and innovation pharma stocks are listed drug makers that supply fermentation ingredients, complex active ingredients and branded and generic medicines. Their earnings depend on customer contracts, regulatory approvals and the progress of new products. This list looks at three of them, Concord Biotech, Neuland Laboratories and Glenmark Pharmaceuticals, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which biopharma, API and innovation pharma stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Concord Biotech, Neuland Laboratories and Glenmark Pharmaceuticals. Based on the 23 October 2026 close, Concord Biotech traded at Rs 1,229.3, Neuland Laboratories at Rs 18,865 and Glenmark Pharmaceuticals at Rs 2,166.6. Their return on equity ranges from 12.9% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 21.1%.\"}},{\"@type\":\"Question\",\"name\":\"Why do biopharma, API and innovation pharma stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Biopharma, API and innovation pharma stocks have a strong roadmap in India because global innovators outsource complex manufacturing, and Indian firms with strong science are moving into specialty and innovative medicines. The main drivers are as follows. Complex chemistry. Few suppliers can make difficult molecules at scale. Custom manufacturing. Innovator contracts bring multi-year demand. Innovation pipeline. New drug programmes create fresh growth options. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Concord Biotech performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P\/E of 49.2, above the industry P\/E of 36.0. Looking ahead, the company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.\"}},{\"@type\":\"Question\",\"name\":\"How has Neuland Laboratories performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P\/E of 49.5, above the industry P\/E of 36.0. Looking ahead, the company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.\"}},{\"@type\":\"Question\",\"name\":\"How has Glenmark Pharmaceuticals performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P\/E of 33.4, below the industry P\/E of 35.7. Looking ahead, the company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying biopharma, API and innovation pharma stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying biopharma, API and innovation pharma stocks. Regulatory checks. Plant inspections can affect approvals. Contract timing. Large orders can shift between quarters. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of biopharma, API and innovation pharma stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Biopharma, API and Innovation Pharma Stocks with a strong future roadmap: Concord Biotech, Neuland Laboratories and Glenmark Pharmaceuticals. Compare price, valuation, return on equity and revenue growth as of 23 October 2026.<\/p>\n","protected":false},"author":29,"featured_media":326359,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[15860,3803,15859,11240,15862,15861,15753,8590],"class_list":["post-326361","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-api-and-innovation-pharma-stocks","tag-best-stocks","tag-biopharma","tag-concord-biotech","tag-custom-synthesis-and-research-stocks","tag-fermentation-ingredient-company-shares","tag-glenmark-pharmaceuticals","tag-neuland-laboratories"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["326359"],"rank_math_title":["Biopharma, API and Innovation Pharma Stocks"],"rank_math_description":["Compare 3 biopharma, API and innovation pharma stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 23 Oct 2026."],"rank_math_focus_keyword":["biopharma, API and innovation pharma stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/3-fermentation-based-ingredients-maker-custom-synthesis-specialist-and-research.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/326361","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=326361"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/326361\/revisions"}],"predecessor-version":[{"id":326362,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/326361\/revisions\/326362"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/326359"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=326361"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=326361"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=326361"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}